|Videos|March 15, 2017
Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer
Author(s)Kathleen N. Moore M.D.
Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.
Advertisement
Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Body Image and Sexual Health Challenges After Breast Cancer
2
What Libtayo Means for High-Risk Cutaneous Squamous Cell Carcinoma
3
Minimally Invasive Kidney Cancer Treatments Boosts Patient Recovery
4
What Are Non-Muscle Invasive Bladder Cancer and its Treatment Options?
5
